Axsome therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

About Axsome therapeutics Contact Number

Contact Us. AXSOME THERAPEUTICS, INC. 22 Cortlandt St., 16th floor New York, NY 10007 Phone: +1(212)332-3241 +1(212)332-3241 Fax: +1‍(‍2‍1‍2‍)‍3‍2‍0‍-‍0‍2‍4‍5 Email: [email protected]axsome.com

Contact US: https://www.axsome.com/contact-us

What kind of company is axsome therapeutics inc?

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.

What kind of currency does axsome therapeutics use?

Currency in USD. Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States.

What is the iss score for axsome therapeutics?

The company was founded in 2012 and is based in New York, New York. Axsome Therapeutics, Inc.’s ISS Governance QualityScore as of December 4, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 8. Corporate governance scores courtesy of Institutional Shareholder Services (ISS).

Axsome

25 People Used

See More ››

Axsome Therapeutics: Expanding Treatment for CNS Conditions

Axsome is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS-14. Learn about our pipeline Axsome focuses on CNS conditions including depression, Alzheimer''s disease agitation, migraine, narcolepsy and fibromyalgia.

View Contact ››

Axsome

62 People Used

See More ››

Axsome Therapeutics

Contact Email [email protected] Phone Number +1 (212) 203-5072 Axsome Therapeutics is a biopharmaceutical company developing novel therapies for the treatment of pain and other neurological diseases. By focusing on this therapeutic area, Axsome is addressing growing markets where current treatment options are limited or inadequate.

View Contact ››

Medical

54 People Used

See More ››

Medical Information Axsome Therapeutics

Medical Information. At Axsome, we are committed to supporting healthcare professionals with questions about our novel therapies for central nervous system (CNS) conditions. Please use the form below to request medical information or to contact an Axsome medical professional.

View Contact ››

Axsome

41 People Used

See More ››

Axsome Therapeutics Company Profile

Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020 Content Import Wed, 10/28/2020 - 07:01 Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020 October 28, 2020 This release is a backfill fro…

View Contact ››

Axsome

127 People Used

See More ››

Axsome Therapeutics to Report Fourth Quarter and Full Year

Axsome Contact: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. 22 Cortlandt Street, 16th Floor New York, NY 10007Tel: 212-332-3243Email: [email protected]axsome.com www.axsome.com Axsome

View Contact ››

Business

51 People Used

See More ››

Axsome Therapeutics, Inc. (AXSM) Company Profile & Facts

See the company profile for Axsome Therapeutics, Inc. (AXSM) including business summary, industry/sector information, number of employees, business summary, corporate governance, key …

View Contact ››

Treatment

54 People Used

See More ››

Axsome Therapeutics (AXSM) Company Profile & Overview

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment

View Contact ››

People

53 People Used

See More ››

Narcolepsy Axsome Therapeutics

Narcolepsy affects an estimated 185,000 individuals in the U.S. Narcolepsy has been shown to occur in people of any race, and shows up most commonly in people aged 15‑30. Cataplexy is seen in an estimated 70% of people living with narcolepsy, and is typically triggered by strong emotions like fear, anger, stress, or excitement.

View Contact ››

Axsome

228 People Used

See More ››

Axsome Therapeutics Announces FDA Acceptance and Priority

Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive …

View Contact ››

(CNS)

199 People Used

See More ››

Axsome Therapeutics : Announces FDA Acceptance and

FDA grants Priority Review and sets PDUFA action goal date of August 22, 2021. NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted …

View Contact ››

About

177 People Used

See More ››

Axsome Therapeutics Initiates ACCORD Phase 3 Trial of

About Axsome Therapeutics, Inc. and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of our current product

View Contact ››

Axsome

85 People Used

See More ››

Axsome Therapeutics Stock (AXSM): PDUFA Ahead Seeking Alpha

Axsome Therapeutics has a vast pipeline of CNS drugs. The company has a near-term catalyst, and the stock has shown its mettle earlier. Read more on the PDUFA for AXS-05 here.

View Contact ››

Developing

90 People Used

See More ››

AXSOME THERAPEUTICS, INC. : AXSM Stock Price

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium

View Contact ››

Axsome

67 People Used

See More ››

How to buy Axsome Therapeutics stock

Updated Jun 9, 2021. Fact checked. Axsome Therapeutics, Inc is a biotechnology business based in the US. Axsome Therapeutics shares (AXSM) are listed on the NASDAQ and all prices are listed in US Dollars. Axsome Therapeutics employs 70 staff and has a market cap (total outstanding shares value) of 0.00.

View Contact ››

253-8660

223 People Used

See More ››

Axsome Therapeutics Announces Expedited Development of

To participate in the live conference call, please dial (844) 698-4029 (toll-free domestic) or (647) 253-8660 (international), and use the passcode 9584742. The live webcast can be …

View Contact ››

Axsome

102 People Used

See More ››

Axsome Therapeutics Joins Mental Health America and other

Axsome Contact:Mark JacobsonChief Operating OfficerAxsome Therapeutics, Inc.22 Cortlandt Street, 16th FloorNew York, NY 10007Tel: 212-332-3243Email: [email protected]axsome.comwww.axsome.com

View Contact ››

Axsome

104 People Used

See More ››

Axsome Therapeutics to Report First Quarter 2021 Financial

Axsome Contact: Mark JacobsonChief Operating Officer Axsome Therapeutics, Inc.22 Cortlandt Street, 16th FloorNew York, NY 10007Tel: 212-332-3243Email: [email protected]axsome.com www.axsome.com

View Contact ››

Axsome

99 People Used

See More ››

Re: Axsome Therapeutics, Inc. Draft Registration Statement

Axsome Therapeutics, Inc. September 22, 2015 Page 2 Our Pipeline, page 3 2. On page 5, you state that you plan to request a meeting with the FDA in 2016 to discuss your development plans for AXS-05 for the treatment of agitation in patients with AD. Your table should clearly indicate which phases of clinical trials have been completed.

View Contact ››

Please leave your comments here:

Popular Brands

Abbvie
Amazon
Apple
Asml
Att
Aia
Acc
Adobe